Genomic Health Announces Fourth Quarter and Year-End 2007 Financial Results and Business Progress and 2008 Financia...( - Full-Year Revenue Increased...),Health

- Full-Year Revenue Increased 120 Percent Compared to 2006 -

- Tests Delivered Grew 69 Percent Compared to 2006 -

- Oncotype DX Included in NCCN, ASCO Guidelines -

- Conference Call Today at 4:30 p.m. ET -

REDWOOD CITY, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the fourth quarter and year ended December 31, 2007.

Total revenue increased to $19.3 million in the fourth quarter of 2007 compared to $8.6 million in the fourth quarter of 2006. Total revenue for the year ended December 31, 2007 increased to $64.0 million compared to $29.2 million in 2006. Product revenue from Oncotype DX was $19.3 million in the fourth quarter of 2007 compared to $8.1 million in the fourth quarter of 2006. Product revenue was $62.7 million for the year ended December 31, 2007 compared to $27.0 million in 2006. Contract revenue comprised the balance of total revenue for each of these periods.

"Throughout 2007, and particularly in the fourth quarter, we experienced significant growth in product revenue fueled by increasing physician, patient and payor adoption of Oncotype DX," said Randy Scott, Ph.D., Chairman and Chief Executive Officer of Genomic Health. "We believe that the inclusion of Oncotype DX in both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) guidelines signals a change in the treatment paradigm for patients with early-stage breast cancer. Increasingly, physicians and patients are incorporating individualized molecular information into treatment decisions as standard practice."

Additional Fourth Quarter and Year-End 2007 Finan
'/>"/>